Immediate Hypersensitivity Reactions to Biologic Therapies in Psoriasis and Hidradenitis Suppurativa
This paper reports three cases of recurrent urticarial hypersensitivity to biologic therapies for psoriasis and hidradenitis suppurativa, demonstrating that intradermal testing can confirm drug allergy, guide the discontinuation of culprit agents, and facilitate successful treatment switching to alternative biologics without further reactions.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
The human immune system is a vigilant guardian, designed to identify and destroy invaders like bacteria and viruses. However, in certain chronic skin conditions such as psoriasis and hidradenitis suppurativa, this defense system malfunctions, turning against the body's own tissues and causing persistent inflammation and pain. For decades, managing these stubborn diseases was difficult, but a new class of medicines known as biologic therapies has changed the landscape. These drugs act like precise tools, targeting specific chemical messengers within the immune system that drive the inflammation, effectively turning off the alarm that causes the skin to flare up. While these treatments have been revolutionary, they are not without complications. Sometimes, the very medicines meant to heal can trigger a different kind of alarm: an allergic reaction. Distinguishing between a harmless side effect and a true allergy is critical, because continuing to use a drug that the body is rejecting can lead to increasingly severe reactions, while stopping a safe drug unnecessarily leaves a patient without treatment.
In a recent case report, researchers from Brazil examined three patients who experienced a specific, recurring problem while using these biologic therapies. The patients, suffering from either psoriasis or hidradenitis suppurativa, had developed itchy, red, raised welts on their skin shortly after receiving their injections. These welts, known medically as urticaria, appeared repeatedly with each dose and seemed to get worse over time. Initially, these reactions might have been dismissed as simple irritation at the injection site, a common occurrence with many shots. However, the pattern of the symptoms—recurring and spreading to other parts of the body with every administration—suggested something more significant was happening. The medical team suspected that these patients were developing an immediate hypersensitivity, a type of allergic response where the immune system reacts quickly to the drug, rather than just a local skin irritation.
To investigate this suspicion, the doctors performed a series of careful tests on the three patients. They stopped the suspected medication and waited for the skin to calm down. Then, under strict medical supervision, they applied tiny amounts of the drug to the patients' skin. First, they used a skin prick test, which involves scratching the surface of the skin with a drop of the medicine. In all three cases, this initial test came back negative, showing no reaction. However, the team then performed a more sensitive test called an intradermal test, where a small amount of the diluted drug is injected just beneath the skin's surface. This time, the results were clear: within twenty minutes, the injection sites on all three patients swelled and turned red, confirming that their bodies were indeed reacting to the medication. Crucially, these reactions happened quickly and did not show up later, which helped the doctors rule out a delayed allergy.
Armed with this evidence, the medical team made a decisive change in treatment. They stopped using the specific biologic drug that had caused the allergic reactions and switched the patients to a different type of biologic that worked through a completely different mechanism. For example, one patient who reacted to a drug targeting a specific immune pathway was switched to a drug that blocked a different pathway entirely. The results were immediate and successful. The itchy, spreading welts disappeared completely, and the patients' underlying skin diseases remained under control. None of the three patients experienced any further allergic reactions after the switch. The researchers calculated that the link between the drug and the reaction was highly probable, based on the timing and the test results.
This series of cases highlights an important lesson for doctors and patients alike. When a patient develops recurring hives after receiving a biologic injection, it should not be automatically written off as a minor side effect or local irritation. Instead, it warrants a closer look to determine if a true allergy is present. By using simple skin tests to confirm the diagnosis, doctors can safely avoid the specific drug causing the problem and switch to an alternative that works just as well for the disease but does not trigger the immune system. This approach allows patients to continue receiving the life-changing benefits of modern biologic therapies without the risk of escalating allergic reactions, ensuring that the treatment remains a source of healing rather than a new source of distress.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.